Overview

• Bench tests produced injectable suspensions exceeding 500 mg/mL for albumin, human immunoglobulin, and a COVID‑19 monoclonal antibody.
• The MoNi polyacrylamide copolymer forms a glassy coating that keeps proteins dry and prevents aggregation, yielding smooth, spherical microparticles that flow through standard needles.
• Formulations showed robustness in stress studies, including 10 freeze–thaw cycles and storage at elevated temperatures without signs of breakdown.
• Researchers note MoNi has shown no adverse effects in preclinical models, though human trials have not yet begun.
• The platform has been licensed to a local startup to refine the process and advance toward manufacturing scale‑up and regulatory testing.